Skip to main content
. 2023 Sep 7;52(5):102. doi: 10.3892/ijmm.2023.5305

Figure 3.

Figure 3

Characterization of sensitivity to osimertinib in osimertinib-resistant and -sensitive cells. (A) HCC827 and (B) HCC827-OR cells were treated with various concentrations of osimertinib, and cell viability was evaluated using CCK8 assay. (C) HCC827 and HCC827-OR cells were incubated with various concentrations of osimertinib for 12 days. Cell colonies were stained with crystal violet and images were captured. (D) H1975 and (E) H1975-OR cells were treated with various concentrations of osimertinib, and cell viability was evaluated using CCK8 assay. (F) H1975 and H1975-OR cells were incubated with various concentrations of osimertinib for 10 days. (G) HCC827 and HCC827-OR cells, and (H) H1975 and H1975-OR cells were treated with various concentrations of osimertinib for 24 h, and cell cycle progression was analyzed by flow cytometry. *P<0.05 and **P<0.01. CCK8, Cell Counting Kit 8; ns, not significant.